SEARCH

SEARCH BY CITATION

References

  • 1
    de Souza PL, Friedlander ML. Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am 1992; 6: 76182.
  • 2
    Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer 2003; 97(10 Suppl, ): 263142.
  • 3
    Tavassoli FA. Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol 1988; 1: 40714.
  • 4
    Burger CW, Prinssen HM, Baak JP, Wagenaar N, Kenemans P. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer 2000; 10: 18197.
  • 5
    Dietel M, Hauptmann S. Serous tumors of low malignant potential of the ovary. I. Diagnostic pathology. Virchows Arch 2000; 436: 40312.
  • 6
    Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynaecol Obstet 2003; 83 ( Suppl 1): 13566.
  • 7
    Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31: 53957.
  • 8
    Morris MC, Kaiser P, Rudyak S, Baskerville C, Watson MH, Reed SI. Cks1-dependent proteasome recruitment and activation of CDC20 transcription in budding yeast. Nature 2003; 423(6943): 100913.
  • 9
    Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005; 29: 70723.
  • 10
    Seidman JD, Kurman RJ. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors). Cancer 2002; 95: 6756.
  • 11
    O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005; 29: 103441.
  • 12
    Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbo J, Nesland JM, Danielsen HE. β-Catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 2005; 41: 112734.
  • 13
    Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, Odunsi K. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol, in press.
  • 14
    Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005; 96: 68494.
  • 15
    Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 105365.
  • 16
    Matsuzaki H, Kobayashi H, Yagyu T, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T. Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol 2005; 23: 146372.
  • 17
    Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005; 96: 6717.
  • 18
    Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR, Berchuck A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005; 96: 35561.
  • 19
    Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, Henderson B, Morrison LE, Birrer MJ. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003; 63: 123541.
  • 20
    Milde-Langosch K, Hagen M, Bamberger AM, Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 2003; 22: 16874.
  • 21
    Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol 2001; 32: 80813.
  • 22
    Sui L, Dong Y, Ohno M, Sugimoto K, Tai Y, Hando T, Tokuda M. Implication of malignancy and prognosis of p27(kip1), cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001; 83: 5663.
  • 23
    Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004; 10: 516877.
  • 24
    Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 310.
  • 25
    Ouellet V, Provencher DM, Maugard CM, Page CL, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005; 24: 467287.
  • 26
    Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 19439.
  • 27
    Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2000; 97: 77982.
  • 28
    Pliskova M, Vondracek J, Vojtesek B, Kozubik A, Machala M. Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events. Toxicol Sci 2005; 83: 24656.
  • 29
    Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanagisawa J, Fujii-Kuriyama Y, et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003; 423(6939): 54550.
  • 30
    Khorram O, Garthwaite M, Golos T. Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions. Mol Hum Reprod 2002; 8: 7580.
  • 31
    Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia 2000; 5: 295306.
  • 32
    Horowitz IR, Cho C, Song M, Flowers LC, Santanam N, Parthasarathy S, Ramachandran S. Increased glycodelin levels in gynecological malignancies. Int J Gynecol Cancer 2001; 11: 1739.
  • 33
    Kamarainen M, Leivo I, Koistinen R, Julkunen M, Karvonen U, Rutanen EM, Seppala M. Normal human ovary and ovarian tumors express glycodelin, a glycoprotein with immunosuppressive and contraceptive properties. Am J Pathol 1996; 148: 143543.
  • 34
    Song M, Ramaswamy S, Ramachandran S, Flowers LC, Horowitz IR, Rock JA, Parthasarathy S. Angiogenic role for glycodelin in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 926570.
  • 35
    Mandelin E, Lassus H, Seppala M, Leminen A, Gustafsson JA, Cheng G, Butzow R, Koistinen R. Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Cancer Res 2003; 63: 625864.
  • 36
    Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, Roberts AB. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2003; 63: 828492.
  • 37
    Sawasaki T, Shigemasa K, Shiroyama Y, Kusuda T, Fujii T, Parmley TH, O'Brien TJ, Ohama K. Cyclin E mRNA overexpression in epithelial ovarian cancers: inverse correlation with p53 protein accumulation. J Soc Gynecol Invest 2001; 8: 17985.
  • 38
    Patra D, Wang SX, Kumagai A, Dunphy WG. The Xenopus Suc1/Cks protein promotes the phosphorylation of G(2)/M regulators. J Biol Chem 1999; 274: 3683942.
  • 39
    Shapira M, Ben-Izhak O, Bishara B, Futerman B, Minkov I, Krausz MM, Pagano M, Hershko DD. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer 2004; 100: 161521.
  • 40
    Masuda TA, Inoue H, Nishida K, Sonoda H, Yoshikawa Y, Kakeji Y, Utsunomiya T, Mori M. Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 2003; 9: 56938.
  • 41
    Inui N, Kitagawa K, Miwa S, Hattori T, Chida K, Nakamura H, Kitagawa M. High expression of Cks1 in human non-small cell lung carcinomas. Biochem Biophys Res Commun 2003; 303: 97884.
  • 42
    Gascoyne DM, Hixon ML, Gualberto A, Vivanco MD. Loss of mitotic spindle checkpoint activity predisposes to chromosomal instability at early stages of fibrosarcoma development. Cell Cycle 2003; 2: 23845.
  • 43
    Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, Kim JG, Kim NS. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 2005; 11(2, Part 1): 47382.
  • 44
    Kutay U, Bischoff FR, Kostka S, Kraft R, Gorlich D. Export of importin α from the nucleus is mediated by a specific nuclear transport factor. Cell 1997; 90: 106171.
  • 45
    Brinkmann U. CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. Am J Hum Genet 1998; 62: 50913.
  • 46
    Brustmann H. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study. Gynecol Oncol 2004; 92: 26876.
  • 47
    Peiro G, Diebold J, Lohrs U. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. Am J Clin Pathol 2002; 118: 9229.
  • 48
    Wong AS, Roskelley CD, Pelech S, Miller D, Leung PC, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 2004; 299: 24856.
  • 49
    Scholl FA, Dumesic PA, Khavari PA. Mek1 alters epidermal growth and differentiation. Cancer Res 2004; 64: 603540.
  • 50
    Huntsman D, Resau JH, Klineberg E, Auersperg N. Comparison ofc-Met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 1999; 155: 3438.
  • 51
    Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 30925.
  • 52
    Ueoka Y, Kato K, Wake N. Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway. Mol Cell Endocrinol 2003; 202(1/2): 818.
  • 53
    Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-Met. Int J Cancer 1997; 73: 1515.
  • 54
    Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 147988.
  • 55
    Saitoh K, Takahashi H, Sawada N, Parsons PG. Detection of the c-Met proto-oncogene product in normal skin and tumours of melanocytic origin. J Pathol 1994; 174: 1919.
  • 56
    Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 8028.
  • 57
    Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004; 6: 25161.
  • 58
    Waugh MG, Hsuan JJ. EGF receptors as transcription factors: ridiculous or sublime? Nat Cell Biol 2001; 3(9): E209E211.
  • 59
    Oksvold M, Huitfeldt H, Stang E, Madshus I. Localizing the EGF receptor. Nat Cell Biol 2002; 4(2): E22; author reply E22–E23.
  • 60
    Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002; 157: 92939.
  • 61
    Raabe TD, Deadwyler G, Varga JW, Devries GH. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells. Glia 2004; 45: 197207.
  • 62
    Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004; 64: 204753.
  • 63
    Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 2004; 10: 6695702.
  • 64
    Di Fiore B, Ciciarello M, Lavia P. Mitotic functions of the Ran GTPase network: the importance of being in the right place at the right time. Cell Cycle 2004; 3: 30513.